HomeBUSINESS
BUSINESS

Emicizumab Every Four Weeks Delivers Positive Data, Chugai Plans New Dosage Filing Next Year
(Dec.8.2017)

Chugai Pharmaceutical said on December 7 that its hemophilia A big-seller hopeful emicizumab demonstrated positive efficacy data with its subcutaneous dosing every four weeks - a longer interval versus the once-weekly dosing initially submitted or approved in major markets ...
(LOG IN FOR FULL STORY)